正大天晴骨髓纤维化双靶点新药上市;海西新药任命张明强为研发总裁;默沙东启动首创眼科双抗II/III期研究

药财社
Mar 02

●药闻快报▲关注药财社聚焦医药界▲1正大天晴骨髓纤维化双靶点新药上市2月28日,正大天晴自主研发的1类创新药罗伐昔替尼片(安煦®)正式获中国国家药品监督管理局批准上市。该药适用于中高危原发性或继发性骨髓纤维化成年患者的一线治疗,成为全球首个获批的JAK/ROCK双靶点小分子抑制剂。骨髓纤维化作为一种罕见的骨髓增殖性肿瘤,临床表现为骨髓纤维化及肝脾肿大,且具有较高的急性白血病转化风险。数据显示,中国...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10